Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Saghmos Therapeutics, Inc.

News headline image
Saghmos Therapeutics Announces Presentation at the Citi Global Healthcare Conference
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Presentation at UBS 2024 Biotechnology Private Company Virtual Symposium
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Issuance of U.S. Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Presentation at the Goldman Sachs 45th Annual Global Healthcare Conference
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Issuance of Patent in Japan for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Receipt of Notice of Allowance from Japanese Patent Office for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Notice of Allowance for Second US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator ST-62516
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Appointment of Pharmaceutical Industry Veteran Fred Hassan as Chairman of the Board of Directors
From Saghmos Therapeutics, Inc.
Via Business Wire
News headline image
Saghmos Therapeutics Announces Issuance of US Patent for ST-62516 for the Reduction of Kidney Injury in Patients with Chronic Kidney Disease Undergoing Contrast Procedures
From Saghmos Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.